Results 191 to 200 of about 514,735 (343)

Controlling Release Kinetics of an Adjuvant from a Depot Improves the Efficacy of Local Immunotherapy in Metastatic Cancer

open access: yesAdvanced Science, EarlyView.
We show that intratumoral release of an immunotherapy—CpG —can be tuned with molecular precision by complexing it to an elastin‐like polypeptide (ELP). Injecting ELP‐CpG and an excipient ELP into tumors drives thermally‐triggered phase separation into a micro‐scale “sponge” depot that releases CpG at rates depending on the ELP composition, which ...
Joshua J. Milligan   +16 more
wiley   +1 more source

Immunosuppressant management in palliative care: a systematic review. [PDF]

open access: yesBMC Palliat Care
Birchler KM   +4 more
europepmc   +1 more source

In Situ Programming of the Tumor Microenvironment to Alleviate Immunosuppression for Pancreatic Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
cmExoaCD11b induced the repolarization of immunosuppressive M2 macrophages into pro‐inflammatory M1 phenotype, thereby promoting the proliferation and activation of CD8+ T cells and reversing the immunosuppressive state of the tumor microenvironment.
Man Sun   +14 more
wiley   +1 more source

Weaning of immunosuppression in long-term recipients of living related renal transplants: A preliminary study [PDF]

open access: yes, 1995
Fung, JJ   +5 more
core  

BCG‐Derived Outer Membrane Vesicles Induce TLR2‐Dependent Trained Immunity to Protect Against Polymicrobial Sepsis

open access: yesAdvanced Science, EarlyView.
B‐OMVs, nanoscale vesicles derived from BCG, are identified as effective and safe inducers of trained immunity that protect against sepsis. Through TLR2‐mediated metabolic and epigenetic reprogramming of hematopoietic stem cells, B‐OMVs enhance inflammatory response and phagocytic activity.
Yuan Gong   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy